Skip to main content
Caplight Logo









Orthogon Therapeutics

Orthogon Therapeutics

Private
Canton, MassachusettsHealthcare & Life Scienceshttps://orthogontherapeutics.com/

Last Round

Follow-on Offering

Apr 17, 2026

Total Funding Raised

$23.4M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Orthogon Therapeutics is a biotechnology company that develops small molecule antiviral drugs for polyomavirus infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

antiviral drugsBK virus therapyBKVoral antiviralssmall molecule therapeuticspolyomavirus treatmentfirst-in-class therapyundruggable targetstransplant medicineviral capsid inhibitorimmunocompromised patientsVP1 inhibitorpreclinical biotechdrug discovery platformstructure-based drug designpan-coronavirus inhibitorJCVgram-negative bacterialarge T antigenLTAg

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orthogon Therapeutics Comparables

Compare Orthogon Therapeutics with similar companies based on industry and business-model similarity.

Orthogon Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hybridize Therapeutics
81%
Ipsen
79%
Asahi Kasei
74%

Orthogon Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Follow-on OfferingApr 17, 2026
VC RoundDec 10, 2024
VC RoundJul 24, 2023
Follow-on OfferingNov 8, 2021
Series AMar 8, 2018

Orthogon Therapeutics Investors

Notable investors and investment history

Orthogon Therapeutics investors
InvestorRounds
Healthcare AngelsFollow-on Offering

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors grew 235% MoM, from 651 to 2.2K.

  • Apr 17, 2026

    $11M raised in follow-on offering.

Orthogon Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orthogon Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orthogon Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCanton, Massachusetts
Employee Range3
Year Founded2012
Last FundingApr 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?